CTLA4 and melanoma: Conversely, RNA-seq data from melanoma patients undergoing anti-CTLA-4 therapy revealed a significant downregulation of GSDMD post-treatment (log2FC = -1.1007, p = 0.021), suggesting dynamic modulation of GSDMD in response to distinct immune checkpoint inhibitors (Supplementary Figure 4).